Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Sareum Holdings plc
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=Financials= {| class="wikitable" |+Financials !Year !1 !2 !3 !4 !5 !6 !7 !8 !9 !10 !11 !12 !13 !14 !15 !16 !17 !18 !19 !20 !21 !22 !23 !24 !25 !26 !27 !28 !29 !30 |- ! colspan="31" |Total |- | colspan="31" |Revenue ($1,000s) |- |Orphan Drug Tax Credits | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |- |Product Revenue | - | - | - | - | - | - | - | - | - | 786,126 | 1,619,419 | 1,668,002 | 1,718,042 | 1,769,583 | 1,822,671 | 1,877,351 | 1,933,671 | 1,991,681 | 2,051,432 | 2,112,975 | - | - | - | - | - | - | - | - | - | - |- | colspan="31" |Costs ($1,000s) |- |Manufacturing & Marketing (0%) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |- |In-licensing Royalty (75%) | - | - | - | - | - | - | - | - | - | 589,594 | 1,214,564 | 1,251,001 | 1,288,531 | 1,327,187 | 1,367,003 | 1,408,013 | 1,450,253 | 1,493,761 | 1,538,574 | 1,584,731 | - | - | - | - | - | - | - | - | - | - |- |Clinical Trials | - | 3,000 | 7,500 | 7,500 | 25,000 | 25,000 | 25,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |- |Animal Studies | - | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |- |FDA Fees | - | - | - | - | - | - | - | 619 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |- |NDA/BLA Preparation Fees | - | - | - | - | - | - | - | 1,000 | 1,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |- |Overheads | 4,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |- |Net Cash Flow | - 4,000 | - 4,000 | - 8,500 | - 8,500 | - 26,000 | - 26,000 | - 26,000 | - 1,619 | - 1,000 | 196,531 | 404,855 | 417,000 | 429,510 | 442,396 | 455,668 | 469,338 | 483,418 | 497,920 | 512,858 | 528,244 | - | - | - | - | - | - | - | - | - | - |- |NPV | 636,856 | 736,984 | 852,132 | 989,727 | 1,147,961 | 1,350,055 | 1,582,463 | 1,849,733 | 2,129,055 | 2,449,563 | 2,590,987 | 2,514,052 | 2,411,609 | 2,279,413 | 2,112,570 | 1,905,438 | 1,651,515 | 1,343,312 | 972,200 | 528,244 | - | - | - | - | - | - | - | - | - | - |- |Risk-added Cash Flow | - 40,000 | - 20,000 | - 28,333 | - 28,333 | - 38,806 | - 38,806 | - 38,806 | - 1,999 | - 1,235 | 196,531 | 404,855 | 417,000 | 429,510 | 442,396 | 455,668 | 469,338 | 483,418 | 497,920 | 512,858 | 528,244 | - | - | - | - | - | - | - | - | - | - |- |rNPV | 53,946 | 133,276 | 236,801 | 282,096 | 746,348 | 888,200 | 1,051,330 | 1,497,811 | 1,724,345 | 2,449,563 | 2,590,987 | 2,514,052 | 2,411,609 | 2,279,413 | 2,112,570 | 1,905,438 | 1,651,515 | 1,343,312 | 972,200 | 528,244 | - | - | - | - | - | - | - | - | - | - |- ! colspan="31" |SDC - 1801 |- |Development Stage |Preclinical |Phase 1 |Phase 2 |Phase 2 |Phase 3 |Phase 3 |Phase 3 |Approval |Approval |Ramp |Ramp |Revenue |Revenue |Revenue |Revenue |Revenue |Revenue |Revenue |Revenue |Revenue |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |- |Likelihood of Reaching Revenue |10% |20% |30% |30% |67% |67% |67% |81% |81% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |- | colspan="31" |Revenue ($1,000s) |- |Orphan Drug Tax Credits | - | - | - | - | - | - | - | - | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |Product Revenue | - | - | - | - | - | - | - | - | - |393,063 |809709.619 |834000.907 |859020.934 |884791.56 |911335.31 |938675.37 |966835.63 |995840.7 |1025715.9 |1056487.4 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- | colspan="31" |Costs ($1,000s) |- |Manufacturing & Marketing (0%) | - | - | - | - | - | - | - | - | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |In-licensing Royalty (75%) | - | - | - | - | - | - | - | - | - |294,797 |607282.214 |625500.68 |644265.701 |663593.67 |683501.48 |704006.53 |725126.72 |746880.52 |769286.94 |792365.55 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |Clinical Trials | - |1,500 |3,750 |3,750 |12,500 |12,500 |12,500 | - | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |Animal Studies | - |500 |500 |500 |500 |500 |500 | - | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |FDA Fees | - | - | - | - | - | - | - |310 | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |NDA/BLA Preparation Fees | - | - | - | - | - | - | - |500 |500 | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |Overheads |2,000 | - | - | - | - | - | - | - | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |Net Cash Flow |(2,000) |(2,000) |(4,250) |(4,250) |(13,000) |(13,000) |(13,000) |(810) |(500) |98,266 |202,427 |208,500 |214,755 |221,198 |227,834 |234,669 |241,709 |248,960 |256,429 |264,122 | - | - | - | - | - | - | - | - | - | - |- |NPV |318,428 |368,492 |426,066 |494,863 |573,981 |675,028 |791,232 |924,866 |1,064,528 |1,224,782 |1,295,493 |1,257,026 |1,205,804 |1,139,707 |1,056,285 |952,719 |825,758 |671,656 |486,100 |264,122 | - | - | - | - | - | - | - | - | - | - |- |Risk-added Cash Flow |(20,000) |(10,000) |(14,167) |(14,167) |(19,403) |(19,403) |(19,403) |(1,000) |(617) |98,266 |202,427 |208,500 |214,755 |221,198 |227,834 |234,669 |241,709 |248,960 |256,429 |264,122 | - | - | - | - | - | - | - | - | - | - |- |rNPV |26,973 |66,638 |118,401 |141,048 |373,174 |444,100 |525,665 |748,905 |862,172 |1,224,782 |1,295,493 |1,257,026 |1,205,804 |1,139,707 |1,056,285 |952,719 |825,758 |671,656 |486,100 |264,122 | - | - | - | - | - | - | - | - | - | - |- ! colspan="31" |SDC - 1802 |- |Development Stage |Preclinical |Phase 1 |Phase 2 |Phase 2 |Phase 3 |Phase 3 |Phase 3 |Approval |Approval |Ramp |Ramp |Revenue |Revenue |Revenue |Revenue |Revenue |Revenue |Revenue |Revenue |Revenue |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |Off Patent |- |Likelihood of Reaching Revenue |10% |20% |30% |30% |67% |67% |67% |81% |81% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |100% |- | colspan="31" |Revenue ($1,000s) |- |Orphan Drug Tax Credits | - | - | - | - | - | - | - | - | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |Product Revenue | - | - | - | - | - | - | - | - | - |393,063 |809709.619 |834000.907 |859020.934 |884791.56 |911335.31 |938675.37 |966835.63 |995840.7 |1025715.9 |1056487.4 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- | colspan="31" |Costs ($1,000s) |- |Manufacturing & Marketing (0%) | - | - | - | - | - | - | - | - | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |In-licensing Royalty (75%) | - | - | - | - | - | - | - | - | - |294,797 |607282.214 |625500.68 |644265.701 |663593.67 |683501.48 |704006.53 |725126.72 |746880.52 |769286.94 |792365.55 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |Clinical Trials | - |1,500 |3,750 |3,750 |12,500 |12,500 |12,500 | - | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |Animal Studies | - |500 |500 |500 |500 |500 |500 | - | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |FDA Fees | - | - | - | - | - | - | - |310 | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |NDA/BLA Preparation Fees | - | - | - | - | - | - | - |500 |500 | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |Overheads |2,000 | - | - | - | - | - | - | - | - | - |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |0 |- |Net Cash Flow |(2,000) |(2,000) |(4,250) |(4,250) |(13,000) |(13,000) |(13,000) |(810) |(500) |98,266 |202,427 |208,500 |214,755 |221,198 |227,834 |234,669 |241,709 |248,960 |256,429 |264,122 | - | - | - | - | - | - | - | - | - | - |- |NPV |318,428 |368,492 |426,066 |494,863 |573,981 |675,028 |791,232 |924,866 |1,064,528 |1,224,782 |1,295,493 |1,257,026 |1,205,804 |1,139,707 |1,056,285 |952,719 |825,758 |671,656 |486,100 |264,122 | - | - | - | - | - | - | - | - | - | - |- |Risk-added Cash Flow |(20,000) |(10,000) |(14,167) |(14,167) |(19,403) |(19,403) |(19,403) |(1,000) |(617) |98,266 |202,427 |208,500 |214,755 |221,198 |227,834 |234,669 |241,709 |248,960 |256,429 |264,122 | - | - | - | - | - | - | - | - | - | - |- |rNPV |26,973 |66,638 |118,401 |141,048 |373,174 |444,100 |525,665 |748,905 |862,172 |1,224,782 |1,295,493 |1,257,026 |1,205,804 |1,139,707 |1,056,285 |952,719 |825,758 |671,656 |486,100 |264,122 | - | - | - | - | - | - | - | - | - | - |} {| class="wikitable" |+Assumptions !Description !Value !Commentary |- ! colspan="3" |SDC - 1801 |- |Orphan drug? |No |Orphan if <200,000 U.S. patients |- | colspan="3" |'''Preclinical''' |- |Duration |1 | |- |Annual Cost |$2,000,000 |8 Scientists at $250,000 per scientist |- |Likelihood of Reaching Revenue |10% | |- | colspan="3" |'''Clinical Phase 1''' |- |Duration |1 | |- |Number of Subjects |60 |20-80 |- |Cost Per Patient |$25,000 |$8,000-15,000 |- |Animal Studies Phase 1 |$500,000 | |- |Annual Overhead (Other Costs) | | |- |Likelihood of Reaching Revenue |20% |20% for a chemical pharmaceutical |- | colspan="3" |'''Clinical Phase 2''' |- |Duration |2 | |- |Number of Subjects |300 |100-300 |- |Cost Per Patient |$25,000 |$8,000-15,000 |- |Animal Studies Phase 2 |$1,000,000 | |- |Annual Overhead (Other Costs) | | |- |Likelihood of Reaching Revenue |30% |30% for a chemical pharmaceutical |- | colspan="3" |'''Clinical Phase 3''' |- |Duration |3 | |- |Number of Subjects |3000 |1,000-5,000 |- |Cost Per Patient |$12,500 |$4,000-7,500 |- |Animal Studies Phase 3 |$1,500,000 | |- |Annual Overhead (Other Costs) | | |- |Likelihood of Reaching Revenue |67% |67% for a chemical pharmaceutical |- |'''Approval''' | | |- |Duration |2 |0.5-1 for fast-track |- |FDA Fees (PDUFA II) |$309,647 | |- |NDA/BLA Preparation Fees |$1,000,000 |$500,000-1,000,000 |- |Annual Overhead (Other Costs) | | |- |Likelihood of Reaching Revenue |81% | |- | colspan="3" |'''Financials''' |- |Patient Population |2,000,000 | |- |Annual Revenue Per Patient |$13,000 | |- |Peak Market Penetration |3% | |- |Patient Polpulation Growth Rate |2% | |- |Ramp to Market Peak |2 |Maximum 4 Years |- |Discount Rate |15% | |- |In-licensing Royalty Rate |75% | |- |Manufacturing and Marketing Offset |0% | |- |Year Patent Protection and Revenues End |21 | |- |Annual Ramp Overhead (Other Costs) | | |- |Annual Peak Revenue Overhead (Other Costs) | | |- ! colspan="3" |SDC - 1802 |- |Orphan drug? |No |Orphan if <200,000 U.S. patients |- | colspan="3" |'''Preclinical''' |- |Duration |1 | |- |Annual Cost |$2,000,000 |8 Scientists at $250,000 per scientist |- |Likelihood of Reaching Revenue |10% | |- | colspan="3" |'''Clinical Phase 1''' |- |Duration |1 | |- |Number of Subjects |60 |20-80 |- |Cost Per Patient |$25,000 |$8,000-15,000 |- |Animal Studies Phase 1 |$500,000 | |- |Annual Overhead (Other Costs) | | |- |Likelihood of Reaching Revenue |20% |20% for a chemical pharmaceutical |- | colspan="3" |'''Clinical Phase 2''' |- |Duration |2 | |- |Number of Subjects |300 |100-300 |- |Cost Per Patient |$25,000 |$8,000-15,000 |- |Animal Studies Phase 2 |$1,000,000 | |- |Annual Overhead (Other Costs) | | |- |Likelihood of Reaching Revenue |30% |30% for a chemical pharmaceutical |- | colspan="3" |'''Clinical Phase 3''' |- |Duration |3 | |- |Number of Subjects |3000 |1,000-5,000 |- |Cost Per Patient |$12,500 |$4,000-7,500 |- |Animal Studies Phase 3 |$1,500,000 | |- |Annual Overhead (Other Costs) | | |- |Likelihood of Reaching Revenue |67% |67% for a chemical pharmaceutical |- |'''Approval''' | | |- |Duration |2 |0.5-1 for fast-track |- |FDA Fees (PDUFA II) |$309,647 | |- |NDA/BLA Preparation Fees |$1,000,000 |$500,000-1,000,000 |- |Annual Overhead (Other Costs) | | |- |Likelihood of Reaching Revenue |81% | |- | colspan="3" |'''Financials''' |- |Patient Population |2,000,000 | |- |Annual Revenue Per Patient |$13,000 | |- |Peak Market Penetration |3% | |- |Patient Polpulation Growth Rate |2% | |- |Ramp to Market Peak |2 |Maximum 4 Years |- |Discount Rate |15% | |- |In-licensing Royalty Rate |75% | |- |Manufacturing and Marketing Offset |0% | |- |Year Patent Protection and Revenues End |21 | |- |Annual Ramp Overhead (Other Costs) | | |- |Annual Peak Revenue Overhead (Other Costs) | | |}
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
